Danazol increases the oral bioavailability of midazolam by inactivation of hepatic and intestinal CYP3A in rats

References

• Aiba T, Yoshinaga M, Ishida K, Takehara Y, Hashimoto Y. 2005. Intestinal expression and metabolic activity of the CYP3A subfamily in female rats. Biol Pharm Bull. 28(2):311–315. doi:10.1248/bpb.28.311.
   PubMed Web of Science ®Google Scholar
• Betz G, Miller HH, Hales DB. 1981. Actions of danazol in vivo on cytochrome P-450 and steroidogenic enzymes in rat testis and liver microsomal preparations. Am J Obstet Gynecol. 141(8):962–972. doi:10.1016/s0002-9378(16)32688-6.
   PubMed Web of Science ®Google Scholar
• Borrás-Blasco J, Rosique-Robles JD, Peris-Marti J, Navarro-Ruiz J, Gonzalez-Delgado M, Conesa-Garcia V. 1999. Possible cyclosporin-danazol interaction in a patient with aplastic anaemia. Am J Hematol. 62(1):63–64. doi:10.1002/(sici)1096-8652(199909)62:1 < 63::aid-ajh15 > 3.0.co;2-r.
   PubMed Web of Science ®Google Scholar
• Chang SY, Fancher RM, Zhang H, Gan J. 2010. Mechanism-based inhibition of human cytochrome P4503A4 by domperidone. Xenobiotica. 40(2):138–145. doi:10.3109/00498250903406762.
   PubMed Web of Science ®Google Scholar
• Chovan JP, Ring SC, Yu E, Baldino JP. 2007. Cytochrome P450 probe substrate metabolism kinetics in Sprague Dawley rats. Xenobiotica. 37(5):459–473. doi:10.1080/00498250701245250.
   PubMed Web of Science ®Google Scholar
• Colunga-Pedraza PR, Colunga-Pedraza JE, Garza-Ledezma MA, Jaime-Pérez JC, Cantú-Rodríguez OG, Gutiérrez-Aguirre CH, Rendón-Ramírez EJ, López-García YK, Lozano-Morales RE, Gómez-De León A, et al. 2018. Danazol as first-line therapy for myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk. 18(2):e109–e113. doi:10.1016/j.clml.2017.11.007.
   PubMed Web of Science ®Google Scholar
• Cui T, Wang Q, Tian X, Zhang K, Peng Y, Zheng J. 2020. Piperine is a mechanism-based inactivator of CYP3A. Drug Metab Dispos. 48(2):123–134. doi:10.1124/dmd.119.088955.
   PubMed Web of Science ®Google Scholar
• Fukuno S, Nagai K, Fujiike M, Sasaki Y, Konishi H. 2019. Conflicting alterations in hepatic expression of CYP3A and enzyme kinetics in rats exposed to 5-fluorouracil: relevance to pharmacokinetics of midazolam. Xenobiotica. 49(12):1470–1477. doi:10.1080/00498254.2019.1578004.
   PubMed Web of Science ®Google Scholar
• Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA. 1994. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol. 47(9):1643–1653. doi:10.1016/0006-2952(94)90543-6.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, von Moltke LL, Harmatz JS, Chen G, Weemhoff JL, Jen C, Kelley CJ, LeDuc BW, Zinny MA. 2003. Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. Clin Pharmacol Ther. 74(2):121–129. doi:10.1016/S0009-9236(03)00118-8.
   PubMed Web of Science ®Google Scholar
• Guengerich FP. 2007. Mechanisms of cytochrome P450 substrate oxidation: mini review. J Biochem Mol Toxicol. 21(4):163–168. doi:10.1002/jbt.20174.
   PubMed Web of Science ®Google Scholar
• Higashikawa F, Murakami T, Kaneda T, Kato A, Takano M. 1999. Dose-dependent intestinal and hepatic first-pass metabolism of midazolam, a cytochrome P450 3A substrate with differently modulated enzyme activity in rats. J Pharm Pharmacol. 51(1):67–72. doi:10.1211/0022357991771971.
   PubMed Web of Science ®Google Scholar
• Holm R, Olesen NE, Hartvig RA, Jørgensen EB, Larsen DB, Westh P. 2016. Effect of cyclodextrin concentration on the oral bioavailability of danazol and cinnarizine in rats. Eur J Pharm Biopharm. 101:9–14. doi:10.1016/j.ejpb.2016.01.007.
   PubMed Web of Science ®Google Scholar
• Katzenmaier S, Markert C, Riedel KD, Burhenne J, Haefeli WE, Mikus G. 2011. Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using a limited sampling strategy. Clin Pharmacol Ther. 90(5):666–673. doi:10.1038/clpt.2011.164.
   PubMed Web of Science ®Google Scholar
• Konishi H, Takenaka A, Minouchi T, Yamaji A. 2001. Impairment of CYP3A4 capacity in patients receiving danazol therapy: examination on oxidative cortisol metabolism. Horm Metab Res. 33(10):628–630. doi:10.1055/s-2001-17912.
   PubMed Web of Science ®Google Scholar
• Konishi H, Sumi M, Shibata N, Takada K, Minouchi T, Yamaji A. 2004. Decrease in oral bioavailability of ciclosporin by intravenous pulse of methylprednisolone succinate in rats. J Pharm Pharmacol. 56(10):1259–1266. doi:10.1211/0022357044481.
   PubMed Web of Science ®Google Scholar
• Kotegawa T, Laurijssens BE, von Moltke LL, Cotreau MM, Perloff MD, Venkatakrishnan K, Warrington JS, Granda BW, Harmatz JS, Greenblatt DJ. 2002. In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. J Pharmacol Exp Ther. 302(3):1228–1237. doi:10.1124/jpet.102.035972.
   PubMed Web of Science ®Google Scholar
• Krämer G, Theisohn M, von Unruh GE, Eichelbaum M. 1986. Carbamazepine-danazol drug interaction: its mechanism examined by a stable isotope technique. Ther Drug Monit. 8(4):387–392. doi:10.1097/00007691-198612000-00001.
   PubMed Web of Science ®Google Scholar
• Kusaba J, Kajikawa N, Kawasaki H, Kurosaki Y, Aiba T. 2012. Comparative study on altered hepatic metabolism of CYP3A substrates in rats with glycerol-induced acute renal failure. Biopharm Drug Dispos. 33(1):22–29. doi:10.1002/bdd.1774.
   PubMed Web of Science ®Google Scholar
• Lin HL, Zhang H, Walker VJ, D'Agostino J, Hollenberg PF. 2017. Heme modification contributes to the mechanism-based inactivation of human cytochrome P450 2J2 by two terminal acetylenic compounds. Drug Metab Dispos. 45(9):990–999. doi:10.1124/dmd.117.075846.
   PubMed Web of Science ®Google Scholar
• Matsuda Y, Konno Y, Hashimoto T, Nagai M, Taguchi T, Satsukawa M, Yamashita S. 2015. Quantitative assessment of intestinal first-pass metabolism of oral drugs using portal-vein cannulated rats. Pharm Res. 32(2):604–616. doi:10.1007/s11095-014-1489-x.
   PubMed Web of Science ®Google Scholar
• Ortiz de Montellano PR. 2019. Acetylenes: cytochrome P450 oxidation and mechanism-based enzyme inactivation. Drug Metab Rev. 51(2):162–177. doi:10.1080/03602532.2019.1632891.
   PubMed Web of Science ®Google Scholar
• Ross WB, Roberts D, Griffin PJ, Salaman JR. 1986. Cyclosporin interaction with danazol and norethisterone. Lancet. 1(8476):330. doi:10.1016/s0140-6736(86)90867-6.
   PubMed Web of Science ®Google Scholar
• Shapiro R, Venkataramanan R, Warty VS, Scantlebury VP, Rybka W, McCauley J, Fung JJ, Starzl TE. 1993. FK 506 interaction with danazol. Lancet. 341(8856):1344–1345. doi:10.1016/0140-6736(93)90852-8.
   PubMed Web of Science ®Google Scholar
• Taylor AL, Watson CJ, Bradley JA. 2005. Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol. 56(1):23–46. doi:10.1016/j.critrevonc.2005.03.012.
   PubMed Web of Science ®Google Scholar
• Townsley DM, Dumitriu B, Liu D, Biancotto A, Weinstein B, Chen C, Hardy N, Mihalek AD, Lingala S, Kim YJ, et al. 2016. Danazol treatment for telomere diseases. N Engl J Med. 374(20):1922–1931. doi:10.1056/NEJMoa1515319.
   PubMed Web of Science ®Google Scholar
• White IN. 1978. Metabolic activation of acetylenic substituents to derivatives in the rat causing the loss of heptic cytochrome P-450 and haem. Biochem J. 174(3):853–861. doi:10.1042/bj1740853.
   PubMed Web of Science ®Google Scholar
• Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL. 2005. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet. 44(3):279–304. doi:10.2165/00003088-200544030-00005.
   PubMed Web of Science ®Google Scholar